Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
- Implementing And Optimizing Your eQMS
- Novel Approach To Cancer Explores Severing Its Genetic Supply Line
- Choosing Analytical Technologies At The Right Stage Of Development
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Unlocking The Future Of Cell And Gene Therapies
- Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
- What Goes Into Restarting A Shelved Orphan Drug Candidate?
- A Much-Improved Approach For Understanding And Managing Safety Risks
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1663374966-lab-microscope-mask-research-study]( "Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape")
Navigating Project Optimus And The Rapidly Changing Oncology Development LandscapeProject Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.
-
![GettyImages-1388281743 pharmacy]( "Addressing A Critical Drug Shortage")
Addressing A Critical Drug ShortageA critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.
-
![GettyImages-1439447135-stem-cell-dna]( "Ensuring Product Safety And Purity With Mycoplasma And Sterility Testing")
Ensuring Product Safety And Purity With Mycoplasma And Sterility TestingDiscover how the Applied Biosystems™ MycoSEQ™ Plus system and Applied Biosystems™ SteriSEQ™ Rapid Sterility Testing System can help accelerate your cell therapy manufacturing process.
-
![GettyImages-1306663245-intestinal-organoid-scientist]( "Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids")
Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.
-
![GettyImages-2174865889-scientists-laboratory-equipment-analysis]( "Optimized Product Recovery Using The Drug Product Filtration System")
Optimized Product Recovery Using The Drug Product Filtration SystemExplore strategies to maximize drug product recovery during sterile filtration, minimize hold-up volume, and reduce dilution after PUPSIT to ensure higher yield, improved efficiency, and less waste.
-
![GettyImages-1935725164-disease-cell-blue]( "3D Neurospheres In Healthy And Alzheimer's: iPSC-Derived Neurons")
3D Neurospheres In Healthy And Alzheimer's: iPSC-Derived NeuronsExplore how different ApoE alleles influence Alzheimer's Disease risk using iPSC-derived neurons as well as gain insights into AD mechanisms and potential therapies.
-
![GettyImages-2193144544-scientist-cell-culture-in-lab]( "Cell Type Setting Considerations For Counting Clumpy Cells")
Cell Type Setting Considerations For Counting Clumpy CellsCell clumping can dramatically affect counting accuracy. Learn how declustering, mixing, and aspiration settings influence cell density measurements and help generate more reliable viability.
-
![GettyImages-2163606903-gloves-pipet-cell-culture-assay]( "Rapid Selection Of High-Performance CHO Basal And Feed Media")
Rapid Selection Of High-Performance CHO Basal And Feed MediaA CHO-S bispecific antibody program needed a better basal and feed media combination. Learn how the screening of 180 conditions in 12 weeks identified one that delivered 38% higher titers.
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Engineering Reliability In Cell Therapy Manufacturing")
Engineering Reliability In Cell Therapy ManufacturingA cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.
-
![GettyImages-1585548490-modular-facility-laboratory-drug-development]( "The Open Standard For Plug-And-Produce")
The Open Standard For Plug-And-ProduceTake a look at how standardized, modular production simplifies line integration, reduces engineering effort, and enables faster changeovers. Ideal for teams seeking flexible manufacturing models.
NEWSLETTER ARCHIVE
- 08.26.26 -- Optimizing Cold Chain & Cryo Logistics
- 08.26.26 -- Clinical Success Of Combination Cell Therapy Hinges On Manufacturability
- 08.25.26 -- OPCU: Advancing Large Molecule Programs Through Smarter Fill-Finish Planning
- 08.25.26 -- Why Vector Yield Remains The Biggest Bottleneck In Vivo Gene Therapy
- 08.25.26 -- Reimagine Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
